Investigating a new treatment approach for brittle bone disorder
Mechanistic investigation into Frizzled-2 signaling for treatment of Osteogenesis Imperfecta
This study is looking at a new way to help people with Osteogenesis Imperfecta (OI) by exploring how a specific signaling pathway in the body can boost bone strength and health, which could lead to better treatments for those with fragile bones.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10928717 on NIH RePORTER |
What this research studies
This research focuses on Osteogenesis Imperfecta (OI), a condition that leads to fragile bones and frequent fractures. The study aims to explore the Wnt/Frizzled2 signaling pathway as a potential treatment to increase bone mass and improve skeletal health. By using specific mouse models of OI, researchers will assess how manipulating this signaling pathway can enhance bone formation and reduce related complications. Patients may benefit from insights gained that could lead to more effective therapies for OI.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Osteogenesis Imperfecta, particularly those experiencing frequent fractures or low bone mass.
Not a fit: Patients with Osteogenesis Imperfecta who are not responsive to current treatments or have other complicating health issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve bone health and quality of life for patients with Osteogenesis Imperfecta.
How similar studies have performed: Preliminary studies have shown promising results in using similar approaches to enhance bone mass in animal models, indicating potential for success in this area.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Adeyeye, Mary Ifeoluwa — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Adeyeye, Mary Ifeoluwa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.